Inoveon Corporation, a University of Oklahoma (“OU”) spin-off company, licensed the digital disease management patent and technology from OU and commercialized the service, delivering retinal evaluations for diabetes patients in primary care settings to detect, stage and make management recommendations from 1997-2016.